# Generate Biomedicines

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/generate-biomedicines

- Industry: Biotechnology
- Headquarters: Somerville, US
- Website: www.generatebiomedicines.com/
- Total disclosed funding: $677M
- Latest round: Series C (Sep 14, 2023)
- Investors on record: 15

## About

Based in Massachusetts, US, and founded in 2018 by Molly Gibson (Co-Founder); Gevorg Grigoryan (Co-Founder & CTO); Noubar Afeyan (Founder & CEO), Generate Biomedicines, Inc., formerly known as Flagship VL56, Inc., operates as a therapeutics company that offers solutions for drug discovery and development. In May 2026, Generate Biomedicines, Inc. raised USD 10.4 million in PIPE funding from Nventures.
 
The company offers a biomedicine platform that can produce new medications on demand across a wide range of biologic modalities, including short peptides, complicated antibodies, enzymes, cytokines, and protein compositions that have yet to be identified. The company uses machine learning technology for the identification and validation of targets and treatments, as well as the specificity of target engagement by produced proteins and the cost of identifying and producing clinical candidates. Generate Biomedicines earns revenue through strategic partnerships with pharma companies, licensing its AI-driven Generative Biology™ platform, and advancing proprietary therapeutics into clinical trials. The company will use the May 2026 funding to support its growth in AI-enabled drug discovery.

## Funding rounds

- Series C, Sep 14, 2023, $273M — ARCH Venture Partners, Flagship Pioneering, T Rowe Price, Alaska Permanent Fund Corporation, Amgen Ventures, Altitude Life Science Ventures, 5Y Capital, Abu Dhabi Investment House, Fidelity Investments, Pictet Alternative Advisors, March Capital, Alumni Ventures Group, Modi Ventures, Mirae Asset Capital (China), NVentures
- Series B, Nov 18, 2021, $373M — ARCH Venture Partners, Flagship Pioneering, T Rowe Price, Alaska Permanent Fund Corporation, Altitude Life Science Ventures, 5Y Capital, Abu Dhabi Investment House, Fidelity Investments
- Series A, Sep 10, 2020, $31M — Flagship Pioneering

## Investors

- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series A, Series B, Series C
- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series B, Series C
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series B, Series C
- Alaska Permanent Fund Corporation — Series B, Series C
- Altitude Life Science Ventures (https://capitalatlas.ai/funds/altitude-life-science-ventures) — Series B, Series C
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series B, Series C
- Abu Dhabi Investment House (https://capitalatlas.ai/funds/abu-dhabi-investment-house) — Series B, Series C
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B, Series C
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series C
- Pictet Alternative Advisors (https://capitalatlas.ai/funds/pictet-alternative-advisors) — Series C
- March Capital (https://capitalatlas.ai/funds/march-capital) — Series C
- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Series C
- Modi Ventures (https://capitalatlas.ai/funds/modi-ventures) — Series C
- Mirae Asset Capital (China) (https://capitalatlas.ai/funds/mirae-asset-capital-china) — Series C
- NVentures — Series C